Nuwellis, Inc. (NUWE) Stock

Nuwellis, Inc. (NUWE) is a Healthcare stock trading at $1.12 (as of 2026-08-20), with a market capitalization of $4.08M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Nuwellis, Inc. develops, manufactures, and commercializes medical devices for ultrafiltration therapy, including the Aquadex FlexFlow and Aquadex SmartFlow systems used to treat patients with fluid overload who have not responded to diuretics. The company sells through a direct sales team in the United States and via independent specialty distributors internationally to hospitals and clinics.

Understand Nuwellis, Inc.: how it makes money

Nuwellis develops and sells ultrafiltration therapy medical devices, mainly its Aquadex FlexFlow and Aquadex SmartFlow systems, to hospitals and clinics through direct sales in the United States and independent specialty distributors in select countries.

Each Aquadex treatment uses both the system components (console) and consumable items (disposable blood set and catheter), so the business profit profile depends on driving system adoption and sustaining ongoing consumable use by treating eligible patients.

Business quality (Weak): The company has a focused product platform for fluid overload patients who have failed diuretics, but in the provided data there are no segment or operating KPI breakdowns, and the latest quarter shows a large operating loss.

Bull case

  • Focused therapy indication and defined product platform: Aquadex FlexFlow and Aquadex SmartFlow are indicated for treatment of fluid overload patients who have failed diuretics.
  • High gross margin in the latest reported period: Gross margin was 70.1% for the period ended 2026-03-31.

Bear case

  • Material operating loss in the latest quarter: Operating margin was -190.1% for the period ended 2026-03-31, indicating significant operating costs relative to revenue.
  • No provided segment or operating KPI detail: The provided data does not include reportable segment revenue or operating metrics, making it harder to pinpoint what is driving performance changes.
Valuation — source: SEC EDGAR (first-party)
Price$1.12
Market Cap$4.08M
Price / Sales0.45
FCF Yield-501.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$8.27M
Net Margin-211.9%
Revenue Growth (YoY)-5.4%
EPS Growth (YoY)201.9%
FCF Growth (YoY)12.9%
Financial Health — source: SEC EDGAR
Altman Z-Score-76.15 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderARMISTICE CAPITAL, LLC ($248010.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOJohn L. Erb
Employees38
CountryUS
IPO Date2012-02-16

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Precision Optics Corporation, Inc. (POCI)
  • QT Imaging Holdings, Inc. (QTI)
  • IRIDEX Corporation (IRIX)
  • ENDRA Life Sciences Inc. (NDRA)
  • Autonomix Medical, Inc. Common Stock (AMIX)
  • CollPlant Biotechnologies Ltd. (CLGN)
  • Bluejay Diagnostics, Inc. (BJDX)
  • Catheter Precision, Inc. (VTAK)
NUWE earnings history · NUWE institutional & insider holders · NUWE KPIs & operating metrics · NUWE financials · NUWE investor presentations & press releases · NUWE SEC filings · NUWE peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.